GLUTATHIONE S-TRANSFERASE (GST)
AS A MARKER OF GENETIC RISK
IN CHEMICAL CARCINOGEN INDUCED BLADDER CANCER
Article published in Urologia Polska 1997/50/4.
authors
-
Wiesław Sokołowski 1, Renata Jaskuła-Sztul 2, Ryszard Szpera 1, Krzysztof Szyfter 2
- 1 Oddział Urologii Z. Z. O. Z. Zarz±du Służby Zdrowia MSW w Poznaniu
Ordynator: dr n. med. Wiesław Sokołowski
2 Zakład Genetyki Człowieka PAN w Poznaniu
Kierownik: prof. dr hab. Jerzy Nowak
keywords
-
bladder cancer glutathione S-transferase genotyping
summary
- Objective. Genetic polymorphism was studied in respect to variability of
- chemical carcinogens sensitivity.
- Patients and methods. Using polymerase chain reaction (PCR), genotypes
- of GST Ml and GST Tl were analysed in the group of 34 urinary bladder
- cancer and in 180 controls.
- Results. It was found that a proportions of the wild type and defeted
- genotypes were comparable in patients and controls. However, in urinary
- bladder cancer patients a defect in GST Tl was always accompanied by a
- defect of GST Ml.
- Conclusion. It seems reasonable, to claim that a coincidence of two defected
- GST genes is responsible for an increased susceptibility to carcinogens,
- particularly to those present in tobacco smoke. A correlation of malignacy
- grading with genotypes appearance re±uires more studies.
references
- [1] Bell, D. A., Taylor, J. A., Paulson, D. F., Robertson, C. N., Mohler, J. L.,
- Lucier, G. W.: Genetic risk and carcinogen exposure: A common inherited defect of
- the carcinogen metabolism gene GST Ml that increases susceptibility to bladder
- cancer. J. Natl. Cancer Inst., 1993, 85,1159-1164.
- [2] Brockmóller, J., Kerb, R., Drakoulis, B., Roots, l.-.GSTMl anditszmńantsA
- and B as host factors of bladder cancer susceptibility: A case control study. Cancer
- Res., 1994, 54, 4103-4111.
- [3] Caparoso, N., Landi, M. T., Vineis, ?.:Relevance of metabolic poiymorphisms to
- human carcinogcnesis: Eualuation of epidemiologie evidence. Pharmacogenetics,
- 1991, 1, 4-19.
- [4] Guengerich, F. R, Shimada, T., Raney, K. D., Yun, Ch. H., Meyer, D. J.,
- Ketterer, B., Harris, T. M., Groopman, J. D., Kadlubar, F. ?.:Elucidation of
- catalytic specifities of human cytochrome P450 and GST enzymes and releimnce to
- molecular epidemiology. Environ. Health Perspectives, 1992, 98, 75-80.
- [5] Hirvonen, A., Nylund, L., Kociba, R, Husgafvel-Pursiainen, K., Vainio, H.:
- Modulation of urinary mutagenicity by genetically determined carcinogen metabo-
- lism in smokers. Carcinogenesis, 1994,15, 813-815.
- [6] Iscovitch, }., Castello, R., Esteve,)., Munoz, N., Colanzi, R., Coronel, A.
- Deamezola, I., Tassi, V., Arslan, A.: Tobacco, smoking, occupational exposurc
- and bladder cancer in Argentina. 1987,40, 734-740.
- [7] Jaskuła-Sztul, R., Hirvonen, A., Husgafvel-Pursiainen, K., Szmeja, Z.,
- Szyfter, W., Szyfter, K.: Glutathione S-transferase genotypes as modifiers of
- indwidual susceptibility to smoking related larynx cancer. W: Head & Neck cancer;
- adyances in basic research, pod red.: J. A. Wernera i in., Elsevier, Amsterdam
- 1996, 29-33.
- [8] Kadlubar, F. F.: DNA adducts of carcinogenic aromatic amines. W: DNA adducts:
- Identification and biological significance, pod red. K. Hemminkiego i in., Int. Agency
- Res. Cancer, Lyon 1994,199-216.
- [9] Kihara, M., Kihara, M., Noda, K.: Lung cancer risk of GSTMl null genotype is
- dependent on the extent oftobacco smoke exposure. Carcinogenesis, 1994,15,415-
- 417.
- [10] Lin, H. ]., Han, Ch. Y., Bernstein, D. A., Hsiao, W., Lin, B. K., Hardy, S.:
- Ethnic distribution of the GST Ml null genotype in 1473 individuals and applica-
- tion to bladder cancer susceptibility. Carcinogenesis, 1994,15,1077-1081.
- [U] Mikstacka, R.: Rola transferaz glutationowych w inaktywacji zwi±zków kancero-
- gennych. Post. Biochem., 1988,34,47-578.
- [12] Nakajima, T., Elovaara, E., Anttila, S., Hirvonen, A., Camus, A. M., Hayes,}. D.,
- Ketterer, B., Vainio, H.: Expression and polymorphism of GST in human lungs: Risk
- factors in smoking related lung cancer. Carcinogenesis, 1995,16, 707-711.
- [13] Roots, I., Drakoulis, N., Brockmoller, J.: Polymorphic enzymes and cancer risk:
- Concepts, methodology and data review. W: Pharmacogenetics of Drug Metabolism,
- pod red. W. Kałowa, Pergamon Press, Nowy Jork 1992,815-841.
- [14] Smith, G., Stanley, L. A., Sim, E., Strnage, R. C, Wolf, C. R.: Metabolic
- polymorphisms and cancer susceptibility. Cancer Survey, 1995, 25, 27-65.
- [15] Vainio, H., McGregor, D.: Approaches to the prediction of human cancer risk.
- Pharmacogenetics, 1992, 2, 337-343.
- [16] Vahakangas, K., Pelkonen, O.: Host variations in carcinogen metabolism and
- DNA repair. W: Genetic epidemiology of cancer, pod red. H. T. Lyncha i T. Hiray-
- amy, CRC Press, Boca Raton, 1989, 35-54.
- [17] Wynder, E. I., Goldsmith, R.: The epidemiology of bladder cancer: a second look.
- Cancer, 1977, 40, 1246-1268.
|